08 Nov 2021 --- Hofseth BioCare (HBC) has seen “continued steady progress” with its commercial execution during Q3 2021. Notably, its work to develop a new consumer health brand continued to gather momentum in the quarter, and it is set to move into the launch phase in 2022.
